ChEMBL provides access to a curated database of bioactive molecules and drug discovery research. Search chemical compounds, retrieve molecular structures and properties, explore drug targets and mechanisms of action, and analyze bioactivity measurements from published scientific studies.
Encrypted at rest, isolated from the model
Resolved from an AES-256-GCM vault at the moment of the call and attached to the request — the model never sees the secrets.
Try asking
Search for chemical compounds in ChEMBL database by name, ChEMBL ID, or molecular structure. WHEN TO USE compound_search vs drug_search: • compound_search: Use for ANY molecule lookup by name, ID, or structure (may lack clinical data) • drug_search: Use ONLY when searching by therapeutic indication (e.g., "drugs for diabetes") For a simple drug name lookup like "find aspirin", use compound_search. SEARCH STRATEGIES: • By name: Use 'name' for drug names, synonyms, or trade names (case-insensitive, partial match) • By ID: Use 'chembl_id' for direct lookup when you know the exact identifier (e.g., 'CHEMBL25' for aspirin) • By structure: Use 'smiles' with 'similarity_threshold' (70-100%) for finding structurally similar compounds • Substructure: Use 'smiles' without threshold to find compounds containing that substructure SIMILARITY SEARCH (uses Morgan fingerprints, radius 2, 2048 bits via FPSim2): • 70%: Loose similarity (finds diverse analogs) • 80%: Good starting threshold (finds close analogs) • 90%+: Very strict (finds nearly identical compounds) MAX_PHASE VALUES (clinical development stage): • 4 = Approved (marketed drug, e.g., FDA/EMA approved) • 3 = Phase 3 Clinical Trials • 2 = Phase 2 Clinical Trials (includes INN applications) • 1 = Phase 1 Clinical Trials (includes USAN applications) • 0.5 = Early Phase 1 • -1 = Unknown clinical phase • NULL = Preclinical compound (bioactivity data only) RETURNED DATA INCLUDES: • Molecular properties: MW, ALogP (lipophilicity), PSA, HBA, HBD, rotatable bonds, aromatic rings • QED (Quantitative Estimate of Drug-likeness): 0-1 scale, higher = more drug-like • Chirality: 0=racemic, 1=single stereoisomer, 2=achiral, -1=unchecked • Rule of Five: MW<500, ALogP<5, HBD<5, HBA<10 (compounds with 0-1 violations are Ro5 compliant) • ATC classifications, cross-references to external databases, molecule hierarchy (parent/salt forms) TIPS: • For approved drugs, add max_phase=4 • ChEMBL uses compound 'families' - salts map to parent compounds • Use get_bioactivity after finding compounds to get their target activities • Properties are calculated on parent (salt-free) form EXAMPLES: • Find aspirin: name='aspirin' or chembl_id='CHEMBL25' • Find kinase inhibitors: name='nib', max_phase=4 • Find structural analogs: Use SMILES with similarity_threshold=80
Retrieve bioactivity measurements (IC50, Ki, EC50, etc.) for compound-target interactions. WORKFLOW: Use target_search or compound_search first to get ChEMBL IDs, then query bioactivity. ACTIVITY TYPES (standard_type field): • IC50: Half-maximal inhibitory concentration (most common for inhibitors) • Ki: Inhibition constant (binding affinity, independent of substrate concentration) • Kd: Dissociation constant (direct binding measurement) • EC50: Half-maximal effective concentration (for agonists) • AC50: Half-maximal activity concentration • Potency/ED50: Effective dose measurements pChEMBL VALUE (recommended for filtering - standardized potency): • Definition: -log10(molar IC50/Ki/Kd/EC50/AC50/Potency/ED50) • Only calculated when: standard_relation='=' AND standard_units='nM' AND value>0 • pChEMBL 9 = 1 nM (highly potent, drug-like) • pChEMBL 7 = 100 nM (potent) • pChEMBL 6 = 1 µM (moderate) • pChEMBL 5 = 10 µM (weak) • pChEMBL 3 = 1 mM (very weak) • Use min_pchembl >= 6 for µM or better activity • Use min_pchembl >= 7 for sub-100nM potency (drug-like) ASSAY TYPES (assay_type field): • B (Binding): Direct target binding measurements (Ki, Kd) • F (Functional): Biological effect in cells/tissues (EC50, IC50 in cellular context) • A (ADME): Absorption, distribution, metabolism, excretion assays (t1/2, bioavailability) • T (Toxicity): Cytotoxicity, hERG inhibition • P (Physicochemical): Solubility, stability (no biological material) • U (Unclassified): Cannot fit single category DATA VALIDITY FLAGS (data_validity_comment field): • 'Outside typical range': Value unusually high/low for activity type • 'Potential missing data': Incomplete data entry • 'Potential author error': Suspected error in publication • 'Manually validated': Curator confirmed accuracy • 'Potential transcription error': Values differ by 3 or 6 orders of magnitude (unit error) LIGAND EFFICIENCY METRICS (in results when available): • LE (Ligand Efficiency): Activity per heavy atom • BEI (Binding Efficiency Index): Activity per molecular weight • LLE (Lipophilic Ligand Efficiency): pActivity - LogP • SEI (Surface Efficiency Index): Activity per polar surface area TIPS: • Use with ADMET targets to get experimental ADMET data • Combine molecule_chembl_id + target_chembl_id for specific compound-target pairs • Check potential_duplicate flag - may indicate cited (not independent) measurements • activity_comment may indicate 'active'/'inactive' conclusions from depositor • document_chembl_id links to source publication for verification
Search for biological targets (proteins, enzymes, receptors, organisms) in ChEMBL database. SEARCH STRATEGIES: • By name: Use 'target_name' for protein names, families (e.g., 'kinase'), or receptors • By gene: Use 'gene_symbol' for exact gene symbol matches (e.g., 'EGFR', 'BRAF', 'TP53') • By ID: Use 'target_chembl_id' for direct lookup (e.g., 'CHEMBL203' for EGFR) • By organism: Filter results to specific species (e.g., 'Homo sapiens', 'Mus musculus') • By type: Filter by target_type to get specific categories TARGET TYPES (target_type field): • SINGLE PROTEIN: Individual protein (most common, highest confidence bioactivity data) • PROTEIN COMPLEX: Multi-subunit complex (e.g., ion channels, GPCRs with multiple subunits) • PROTEIN FAMILY: Homologous protein groups (broader search, lower specificity) • PROTEIN-PROTEIN INTERACTION: Two interacting proteins • CHIMERIC PROTEIN: Engineered fusion protein • SELECTIVITY GROUP: Panel of related targets for selectivity profiling • ORGANISM: Whole organism (bacteria, parasites, viruses, fungi) • TISSUE: Tissue-level target • CELL-LINE: Cell-based target (phenotypic screening) • NUCLEIC-ACID: DNA/RNA targets • SUBCELLULAR: Subcellular compartments • UNKNOWN: Unclassified targets TARGET CONFIDENCE SCORES (in bioactivity data): • 9: Direct single protein target (highest confidence, most reliable) • 8: Homologous single protein (inferred from related species) • 7: Direct protein complex subunits (multi-subunit target) • 6: Homologous protein complex • 5: Direct protein selectivity group • 4: Homologous selectivity group • 3: Protein not in target complex • 2: Non-protein organism target • 1: Non-molecular target (cell-line, organism, tissue) • 0: Default or uncurated TARGET RELATIONSHIPS (between targets): • EQUIVALENT TO: Same target in different contexts • OVERLAPS WITH: Partially shared components • SUBSET OF: Contains subset of components • SUPERSET OF: Contains additional components RETURNED DATA INCLUDES: • Target components: Protein subunits with accessions (UniProt) • GO annotations: Gene Ontology terms for molecular function, biological process, cellular component • Cross-references: Links to UniProt, PFAM, InterPro, IntAct, Reactome, etc. • Species information: Tax ID and organism name TIPS: • Use gene_symbol for exact matches - more precise than target_name • After finding a target, use get_bioactivity with target_chembl_id to find active compounds • For drug discovery, focus on SINGLE PROTEIN targets (confidence >= 7) • Filter by organism='Homo sapiens' for human targets • Check GO annotations to understand target function and localization
Retrieve mechanism of action (MoA) data for approved drugs and clinical candidates. PURPOSE: Understand how drugs interact with their targets - essential for drug repurposing, understanding polypharmacology, and target validation. ACTION TYPES (action_type field): • INHIBITOR: Blocks target activity (most common for small molecule drugs) • ANTAGONIST: Blocks receptor activation (prevents agonist binding) • AGONIST: Activates receptor (mimics natural ligand) • BLOCKER: Blocks ion channels or transporters • MODULATOR: Alters target activity (often allosteric mechanism) • POSITIVE ALLOSTERIC MODULATOR: Enhances agonist response without binding orthosteric site • NEGATIVE ALLOSTERIC MODULATOR: Reduces agonist response • OPENER: Opens ion channels (increases conductance) • ACTIVATOR: Increases enzyme activity • PARTIAL AGONIST: Partially activates receptor (submaximal efficacy) • INVERSE AGONIST: Reduces constitutive (basal) receptor activity • SUBSTRATE: Acts as substrate for enzyme (e.g., prodrugs) • RELEASING AGENT: Causes release of neurotransmitters • SEQUESTERING AGENT: Binds and removes target (e.g., antibodies) KEY RESULT FIELDS: • direct_interaction: true = drug binds directly to target; false = indirect effect • disease_efficacy: true = target is directly relevant to therapeutic effect • molecular_mechanism: Specific molecular action (e.g., 'Cyclooxygenase inhibitor') • binding_site_name/comment: Where drug binds on target (e.g., 'ATP binding site') • selectivity_comment: Notes on target selectivity vs related proteins • mechanism_refs: Literature references supporting the mechanism BINDING SITE INFORMATION: Results may include binding site details when known: • site_name: Named binding pocket (e.g., 'Colchicine site', 'ATP binding domain') • site_id: ChEMBL binding site identifier for further lookup WORKFLOW: 1. Find compound: compound_search(name='imatinib') 2. Get mechanisms: get_mechanism(molecule_chembl_id='CHEMBL941') 3. Validate with bioactivity: get_bioactivity(molecule_chembl_id='CHEMBL941', target_chembl_id='CHEMBL1862') TIPS: • MoA data is manually curated for approved drugs and advanced clinical candidates • Use target_chembl_id to find all drugs acting on a specific target (drug repurposing) • Check mechanism_refs for original publications supporting the mechanism • Combine with get_bioactivity to see quantitative potency data for mechanism targets • Parent compound IDs work even when mechanism is stored under salt form
Search for approved drugs and clinical candidates by therapeutic indication. PURPOSE: Find drugs used for specific diseases, identify approved treatments, explore drug repurposing opportunities. DRUG VS COMPOUND: • Drug: Compound with assigned INN/USAN name + clinical data (max_phase ≥ 1) • Compound: Any molecule in ChEMBL (may only have bioactivity data) • Use compound_search for broader chemical searches, drug_search for therapeutic applications MAX_PHASE VALUES (clinical development stage): • 4 = Approved (marketed drug, e.g., FDA/EMA approved) • 3 = Phase III Clinical Trials (large-scale efficacy trials) • 2 = Phase II Clinical Trials (proof of concept, includes INN applications) • 1 = Phase I Clinical Trials (safety, includes USAN applications) • 0.5 = Early Phase 1 (exploratory studies) • -1 = Unknown clinical phase (status uncertain) • NULL = Preclinical only (no human trials, compound_search more appropriate) SAFETY FLAGS IN RESULTS: • black_box_warning: 1 = has FDA black box warning (serious safety concern) • withdrawn_flag: true = withdrawn from one or more markets • withdrawn_reason: Why drug was withdrawn (e.g., hepatotoxicity, cardiac effects) • withdrawn_country/year/class: Details about market withdrawal INDICATION SEARCH: • Uses MeSH (Medical Subject Headings) disease terminology • Also searches EFO (Experimental Factor Ontology) terms • Partial matching supported (e.g., 'cancer' matches 'breast cancer', 'lung cancer') • Common indications: hypertension, diabetes, cancer, asthma, depression, arthritis INDICATION DETAILS IN RESULTS: • mesh_id/mesh_heading: MeSH disease classification • efo_id/efo_term: EFO disease ontology • max_phase_for_ind: Highest phase achieved for this specific indication TIPS: • Use only_approved=True for marketed drugs only • Check black_box_warning and withdrawn_flag for safety information • After finding drugs, use get_mechanism to understand their molecular targets • Use max_phase=3 to include drugs in late-stage trials (potential future approvals) WORKFLOW EXAMPLE: 1. drug_search(indication='hypertension', only_approved=True) → Find approved antihypertensives 2. get_mechanism(molecule_chembl_id='CHEMBL1200749') → Get targets for amlodipine 3. get_bioactivity(target_chembl_id='CHEMBL1940') → Find other L-type calcium channel blockers
Retrieve ADMET-related molecular properties for drug-likeness assessment. IMPORTANT: ChEMBL provides CALCULATED molecular properties (from structure), not experimental ADMET data. For experimental ADMET measurements, use get_bioactivity with specific ADMET target ChEMBL IDs. CALCULATED PROPERTIES (what this tool returns): • ALogP: Calculated lipophilicity (Wildman-Crippen LogP) - Optimal for oral drugs: 1-3 - < 0: Poor membrane permeability - > 5: Poor solubility, potential accumulation • Molecular Weight (full_mwt): Total molecular weight including salts • Molecular Weight (mw_freebase): Parent compound molecular weight only • H-bond Donors (HBD): Rule-of-5 limit < 5 • H-bond Acceptors (HBA): Rule-of-5 limit < 10 • Polar Surface Area (PSA): Topological PSA - < 140 Ų: Good oral absorption - < 90 Ų: Better CNS penetration (crosses BBB) • Rotatable Bonds (RTB): < 10 for good oral bioavailability • Heavy Atoms: Non-hydrogen atom count • Aromatic Rings: < 4 recommended for drug-likeness • Rule-of-5 Violations (num_ro5_violations): 0-1 preferred • Rule-of-3 Pass (ro3_pass): Y/N for fragment-like properties • QED Weighted: Quantitative Estimate of Drug-likeness (0-1 scale) - Higher = more drug-like profile - Based on MW, ALogP, HBD, HBA, PSA, RTB, aromatic rings, alerts DRUG-LIKENESS GUIDELINES: • Lipinski Rule-of-5: MW < 500, ALogP < 5, HBD ≤ 5, HBA ≤ 10 • Veber Rules: PSA ≤ 140 Ų, RTB ≤ 10 • Lead-like: MW < 450, ALogP -4 to 4.2, RTB ≤ 10 FOR EXPERIMENTAL ADMET DATA (use get_bioactivity with these targets): • hERG (CHEMBL240): Cardiac safety (K+ channel, IC50 > 10µM preferred) • CYP3A4 (CHEMBL340): Major metabolizing enzyme (avoid strong inhibition) • CYP2D6 (CHEMBL289): Polymorphic CYP (genetic variability concerns) • CYP2C9 (CHEMBL3397): Warfarin metabolism (drug interactions) • P-glycoprotein (CHEMBL4302): Drug efflux transporter (affects BBB, gut) WORKFLOW EXAMPLE: 1. Get calculated properties: get_admet(molecule_chembl_id='CHEMBL941') 2. Check hERG liability: get_bioactivity(molecule_chembl_id='CHEMBL941', target_chembl_id='CHEMBL240') 3. Check CYP inhibition: get_bioactivity(molecule_chembl_id='CHEMBL941', target_chembl_id='CHEMBL340')
One endpoint, the same key, whichever client you use.
~/Library/Application Support/Claude/claude_desktop_config.json (Mac) · %APPDATA%\Claude\claude_desktop_config.json (Windows)
Replace API_KEY with your own key.
Already have an "mcpServers" section in your config? Just add the server entry inside it.
Discovery, routing, credentials, tool scoping and execution logs all happen at the gateway→connections stay ACTIVE with no work from you
ChEMBL MCP runs through a gateway that holds the credentials, scopes the access and records every call.
Managed auth, hosted MCP servers, and every Gmail tool your agent needs.
Free to start.